Industry B BioPharm International
Lonza Adds Bioconjugation Suites in Visp to Meet Rising ADC Demand
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry B BioPharm International
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
Clinical B BioPharm International
The first-in-class molecule, licensed to Dianthus as DNTH212 outside Greater China, is designed to block type 1 interferon production and BAFF/APRIL-driven B-cell activity with a single drug.
Clinical
Labiotech
ESMO 2026 was the hotspot for cancer research readouts, with encouraging trials across indications and therapeutic candidates. The post ESMO 2026: readouts and highlights at the oncology summit appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized us…
Industry P PLOS Biology
by Kyu-Chan Cho, Won-Jae Lee Microbes are increasingly recognized as modulators of host behavior, but the underlying mechanisms are poorly understood. A new PLOS Biology study reveals a microbiome-to-gut-to-neuron pathway linking developmental microbial exposure to later food avo…
Industry P PLOS Biology
by Joanna Clarke, Sarah Jäkel Research into neurodegeneration is often confined to a single disease, cell type or mechanism. A new collection of articles explores neurodegeneration within its physiological context, looking beyond diseased neurons to the surrounding tissue microen…
Industry
TechCrunch Biotech and Health
At TechCrunch Founder Summit 2026, happening November 4 at SoWa Power Station in Boston, networking powered by Braindate is designed to make those conversations easier to find, whether they are in 1:1 or small-group on-site meetings. Register before the event starts to save up to…
Industry
PharmaVoice
The dreaded patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
Industry
MedCity News
For life science employers who offer these benefits should pay particular attention to new state laws and regulations to ensure continued compliance. The post It’s A TRAP! Employer Concerns for Tuition Reimbursement and Other Employee Repayment Agreements appeared first on MedCit…
Agriculture
AgriBusiness Global
Syngenta Group, the world’s largest agricultural technology company by revenue1, reported its financial results for the first nine months and... The post Syngenta Group Reports 9M 2026 Results With Higher Profitability appeared first on AgriBusiness Global.
Funding
PharmaVoice
Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its buzzy bispecific.
Industry B BioPharm International
HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
Industry
European Biotechnology
From Berlin biotech NOXXON through a strategic realignment and considerations of cryptocurrency investments, and now back to drug development: TME Pharma has found a potential partner for its lead drug candidate NOX-A12 in Japanese biotech company TMS. For now, however, the compa…
Regulatory P Pharmaceutical Executive
Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
Industry
European Biotechnology
Swiss DARPin specialist Molecular Partners is shifting its entire focus to radiopharmaceuticals and plans to cut up to 55 jobs. According to the company, its cash reserves will last until the end of 2027. But behind the strategic overhaul lies an increasingly strained financial p…
Industry
TechCrunch Biotech and Health
5 days to save up to $100, plus a second pass for free to TechCrunch Founder Summit 2026 in Boston on November 4. Register now.
Industry P Pharmaceutical Commerce
The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.
Regulatory B BioPharm International
The IL-23p19 inhibitor tildrakizumab becomes the third drug in its class approved for psoriatic arthritis, and the only one given exclusively by a healthcare provider.
Agriculture
CropLife
Post-harvest evaluations and field-specific fertility planning can help your grower-customers protect profitability and yield potential. The post 4 Ways to Build a Smarter, More Profitable Fertility Program appeared first on CropLife.
Clinical
Pharmaceutical Technology
Following this MHRA label expansion, UK patients with β-thalassemia and sickle cell disease aged five and up can now receive Casgevy.
Industry
BioPharma Dive
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.
Regulatory
MedTech Dive
The company notified customers this month that it will discontinue Medline brand beds and associated products and exit the market.
Industry P Pharmafile
Private asset manager Capital Dynamics has invested €14m in Celsus Holding, the holding company through which private equity fund Silver Economy Fund owns Italian outpatient diagnostics and community healthcare platform CareHub. The investment, made through Capital Dynamics’ Dire…
Industry
Pharmaceutical Technology
Sales for Eli Lilly’s Mounjaro and Zepbound topped $16bn, exceeding total revenue for many big pharma players.
Software P Paired Ends
Tacit knowledge, AI and biosecurity, field building, chat with DNA, Nextflow, AI in academia and science, R package development, peer review
Clinical
Clinical Trials Arena
Geron will now focus on Rytelo’s combinatory potential alongside SoC JAK inhibitor, Jakafi in frontline myelofibrosis. The post Geron winds down Phase III rare blood cancer trial after muted efficacy appeared first on Clinical Trials Arena.
Industry
EMA Press
PRAC starts review of depression and anxiety medicine Deanxit (flupentixol/melitracen)PRAC has started a review of Deanxit, a fixed-dose combination medicine for treating…, Agenda Agenda of the PRAC meeting 26 - 29 October 2026Draft Reference Number: EMA/PRAC/227255/2026…, PRAC s…
Software
LifeSciVC
AI is transforming industries, and biopharma is no exception. AI will help make better drugs, hopefully more efficiently, and will aid in bringing those medicines to patients with expedience. But here’s my prediction: AI will drive a wave of drug The post The Fruits of AI Drug Ab…
Industry P pharmaphorum
Aspen, Bambusa close IPOs as Corxel takes SPAC route Phil.Taylor Fri, 30/10/2026 - 11:00
Clinical A Applied Clinical Trials
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Industry
BioPharma Dive
The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.
Research
Clinical Trials Arena
Starton Therapeutics has entered a clinical trial agreement with the Stanford School of Medicine to assess its STAR-LLD candidate alongside a new CAR-T cell therapy for MM. The post Starton and Stanford to study STAR-LLD combination in MM appeared first on Clinical Trials Arena.
Industry P Pharmaceutical Executive
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Industry P Pharmaceutical Executive
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Regulatory A Applied Clinical Trials
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
Industry P Pharmaceutical Executive
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
Industry P pharmaphorum
Sanofi eyeing pipeline deals ahead of Dupixent patent loss Phil.Taylor Fri, 30/10/2026 - 09:55
Industry
Pharmaceutical Technology
Glenmark Pharmaceuticals has inaugurated an approximately 160,000ft² distribution hub in Allentown, Pennsylvania, US.
Clinical
Clinical Trials Arena
Nuvation Bio is set to expand its pivotal Phase III SIGMA trial into Europe to evaluate safusidenib in patients with IDH1-mutant glioma. The post Nuvation Bio to broaden Phase III glioma trial into Europe appeared first on Clinical Trials Arena.
Funding
Pharmaceutical Technology
Dren Bio has secured $350m in an oversubscribed private financing round to advance its primary investigational therapy, dibotatug, through late-stage clinical evaluation, regulatory submission, and potential commercialisation.
Regulatory
MHRA
Children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, can now be treated with Casgevy (exagamglogene autotemcel), following an extension of its UK authorisation by the MHRA.